

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*The Offer to Purchase and related documents do not constitute an offer to buy or the solicitation of an offer to sell Notes in any circumstances in which such offer is unlawful. In those jurisdictions where the securities, blue sky or other laws require the Offer to be made by a licensed broker or dealer, the Offer will be deemed to be made on behalf of the Company by one or more registered brokers or dealers licensed under the laws of such jurisdiction. Neither the delivery of this Offer to Purchase and related documents nor any purchase of Notes will, under any circumstances, create any implication that the information contained therein is current as of any time subsequent to the date of such information.*



Hua Han Health Industry Holdings Limited

華瀚健康產業控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 587)

**US\$150,000,000 7% SENIOR NOTES DUE 2019**

**(Stock Code: 5676)**

**FURTHER ANNOUNCEMENT IN RELATION TO THE OFFER TO  
PURCHASE FOR CASH ANY**

**AND**

**ALL OUTSTANDING 7.00% SENIOR NOTES DUE 2019**

Reference is made to the announcement of the Company dated 29 November 2016 (the “**Announcement**”) regarding the offer to purchase for cash any and all outstanding 7.00% Senior Notes due 2019 from each holder of the Senior Notes. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Company wishes to announce that, the Company has extended the Expiration Time from 4:00 p.m. London time, January 20, 2017 to 4:00 p.m., London time, January 23, 2017. The Offer to Purchase Payment Date is expected to remain the same as set out in the Announcement, i.e. 25 January 2017, being the second Business Day in London following the Expiration Time. All other terms of the Offer set forth in the Offer to Purchase, including, without limitation, the procedures for tendering the Notes and the Consideration, remain unaffected.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

## **SUSPENSION OF TRADING**

At the request of the Company, trading in the shares (stock code: 00587) and debt securities (stock code: 05676) of the Company has been suspended on the Stock Exchange since 9:00 a.m. on Tuesday, 27 September 2016, and shall remain suspended until further notice.

By Order of the Board of  
**Hua Han Health Industry Holdings Limited**  
**Zhang Peter Y.**  
*Chairman*

Hong Kong, 20 January 2017

*As at the date of this announcement, the Board comprises Mr. Zhang Peter Y., Mr. Deng Jie, Mr. Zhou Chong Ke, Mr. Chen Lei and Mr. Luo Zhan Biao as executive Directors, Mr. Tarn Sien Hao as non-executive Director, and Professor Lin Shu Guang, Professor Zhou Xin and Mr. Tso Sze Wai as independent non-executive Directors.*